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SUMMARY 
The molecular basis for complete hypoxanthine guanine phosphoribosyltransferase (HPRT) deficiency has 
been determined in a patient with Lesch-Nyhan syndrome. A B-lymphoblastoid cell line derived from this 
patient expresses normal amounts of HPRT mRNA yet no detectable immunoreactive protein as determined 
by radioimmunoassay. These findings suggest either a decreased rate of translation or accelerated degradation 
due to enhanced proteolytic susceptibility. cDNAs synthesized from this patient’s RNA have a single nucleotide 
(nt) substitution, a C --, A transversion at nt 222. RNase A cleavage analysis confirms the presence of a 
mutation at this position within mRNA isolated from lymphoblasts from patient A.C. This transversion predicts 
a phenylalanine to leucine replacement at amino acid position 73 in the translated protein. We have designated 
this mutant HPRT,,,,. The mutation in HPRTFlint disrupts a strongly conserved region among PRTases from 
Escherichiu coli, rodents and man, suggesting an important role for this region for the normal function of HPRT. 
Since it is unlikely that this amino acid substitution alters the translational rate, we hypothesize that disruption 
of the secondary structure within this region renders HPRTFli,t more susceptible to proteolysis. 
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phoribosyltransferase; IMP, inosine monophosphate; nt, nucle- 
otide(s); RIA, radioimmunoassay. 
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INTRODUCTION 
Hypoxanthine guanine phosphoribosyltransferase 
(HPRT; EC 2.4.2.8) is a purine salvage enzyme that 
catalyzes the conversion of hypoxanthine and 
guanine to IMP and GMP, respectively. Human 
HPRT mutants were isolated over 25 years ago and 
became the basis for development of a DNA- 
mediated transformation system (Szybalska and 
Szybalski, 1962; Scangos and Ruddle, 1981). Partial 
deficiency of this enzyme results in hyperuricemia 
and a severe form of gout (Kelley et al., 1967). 
Complete HPRT deficiency causes the Lesch- 
Nyhan syndrome, a disease manifested by hyperuri- 
cemia, hyperuricaciduria, uric acid renal stones and 
severe neurological abnormalities (Lesch and 
Nyhan, 1964; Seegmiller et al., 1967). 
The determination of mutations responsible for 
HPRT deficiency in man has been limited in the past 
to the study of mutations which do not greatly affect 
the intracellular enzyme concentration. The identifi- 
cation of the complete amino acid sequence of the 
normal enzyme (Wilson et al., 1982a) and the deter- 
mination of amino acid substitutions in four mutant 
proteins (Wilson et al., 1986) have led to a prelimi- 
nary understanding of the roles of certain domains 
with respect to the catalytic function of HPRT 
(Argos et al., 1983). 
To extend our understanding of the molecular 
basis of HPRT-deficient states, we have undertaken 
the characterization of mutant forms of human 
HPRT. HPRT-deficient subjects are a phenotypi- 
tally heterogeneous population with regard to 
enzyme activity and concentration. This phenotypic 
variability reflects the occurrence of new and inde- 
pendent mutations at the HPRT locus (Yang et al., 
1984; Wilson et al., 1986). More than 75% of these 
F H 
mutants have normal amounts of HPRT specific 
mRNA. Furthermore, in all but five cases described 
to date, transcript size is grossly normal (Wilson 
et al., 1986; Yang et al., 1984). These characteristics, 
together with available techniques for cDNA clon- 
ing, provide the necessary rationale and tools for the 
identification of mutations which lead to dys- 
functional HPRT. 
A subject (A.C.) with the Lesch-Nyhan syn- 
drome, has been previously characterized. Erythro- 
cytes and lymphoblasts from A.C. had undetectable 
HPRT activity (< 0.1 mU/mg or < 0.7 y0 of control 
values). Immunoreactive protein, as determined by 
RIA using polyclonal anti-human HPRT, was also 
undetectable (< 1.5 ng CRM/mg or < 0.5 y0 of con- 
trol values). HPRT-specific mRNA from A.C. 
lymphoblasts was grossly normal with respect to size 
and amount on Northern-blot analysis (Wilson 
et al., 1986). We have identified a single nucleotide 
substitution in HPRT cDNA clones derived from 
A.C. mRNA. The resultant amino acid change 
replaces phenylalanine with leucine in a region of the 
protein strongly conserved in E. coli, rodent and 
human phosphoribosyltransferases (Hershey and 
Taylor, 1986). These data suggest an important role 
for Phe-73 in maintaining an enzymatically active 
protein. 
EXPERIMENTAL AND DISCUSSION 
(a) cDNA cloning and recombinant analysis 
B-lymphoblastoid cells were established from 
lymphocytes isolated from patient A.C. as previously 
described (Wilson et al., 1982b). RNA was isolated 
Fig. 1. Strategy for sequencing mutant cDNA clones. The entire cDNA was sequenced in both directions using HPRT-specific oligomers 
(arrows 1 + 5) or the Ml3 universal primer (unnumbered arrows). The nucleotide sequences of HPRT-specific primers 1 through 5 are 
listed in Table I. The site of the mutation is indicated by a triangle. Stippled bar, HPRT-coding sequence; single line, HPRT-untranslated 




HPRT specific oligodeoxynucleotide primers 
Oligodeoxy- Sequence (5’ + 3’) Priming site a Strand’ 
nucleotide (nt) 
1 AGTGATGATGAACCAG 31- 47 
2 CACTGAATAGAAATAGT 251-267 _ 
3 GATATAATTGACACTGG 403-419 _ 
4 CCCCTGTTGACTGGTCA 337-321 + 
5 AGTCCTGTCCATAATTA 138-122 + 
a Corresponds to the nucleotides of sense strand of HPRT cDNA where the A of the ATG start codon is position 1. Note that primers 
4 and 5 hybridize to the sense strand and are therefore the complement of the HPRT cDNA sequence. 
’ The strand to which the primer anneals is represented as either sense ( + ) or antisense ( - ). 
using guanidium isothiocyanate (Chirgwin et al., 
1979) and then subjected to oligo-d(T) column 
chromatography to obtain poly(A) + RNA (Aviv and 
Leder, 1972). Approximately 10 pg of poly(A)’ RNA 
were used to synthesize an oligo-d(T)-primed library 
(Okayama and Berg, 1982; Gubler and Hoffman, 
1983), which was cloned into &gtll (Young and 
Davis, 1983). 
Recombinant phages were screened with an 
[ a-32P]dCTP-labeled MspI-TuqI (160 nt) fragment 
of normal HPRT cDNA containing portions of 
exons 1 and 3 and all of exon 2 (Brennand, 1983). 
Four HPRT-positive recombinants were isolated: 
pHPAC1, pHPAC2, pHPAC8 and pHPAC12. 
Restriction endonuclease mapping and nucleotide 
sequencing revealed that pHPAC8 and pHPAC12 
were full-length, containing 654 nt of coding se- 
quence, 590 nt of 3’-untranslated sequence and 118 
and 120 nt of 5’-untranslated sequence, respectively. 
pHPAC1 contained only 52 nt of 5’-untranslated 
sequence. 
(b) Sequencing of mutants 
The dideoxynucleotide sequencing strategy for 
pHPAC1, pHPAC8, and pHPAC12 is depicted in 
Fig. 1, and used both HPRT-specific primers and 
the Ml3 universal primer (Bethesda Research Labo- 
ratories; Biggin et al., 1983; Bonthron et al., 1985). 
The positions of the HPRT nucleotide sequence to 
which these primers anneal and the strands to which 
they anneal are shown in Table I. 
Sequencing of pHPAC8 showed two differences 
from normal HPRT sequence, a C + A transversion 
at nt 222 and a G -+ A transition at nt 658. Se- 
quencing of clones pHPAC12 and pHPAC 1 revealed 
only the C + A transversion at 222, indicating that 
the G -+ A transition is probably a cloning artifact. 
Consistent with this conclusion, RNase cleavage 
analysis also failed to detect the transition at nt 658 
(not shown). 
The C + A transversion at nt 222 predicts a 
Phe --f Leu change at aa 73 (Fig. 2). The normal 
abundance of HPRT mRNA in patient A.C. sug- 
gests that one effect of this nucleotide substitution is 
at the level of the primary structure of the protein 
since no immunoreactive protein is detectable in 
lymphoblasts derived from this patient (Wilson 
et al., 1986). Phe-73 is strongly conserved among 
various phosphoribosyltransferases when aligned to 
give maximal overlap of predicted secondary struc- 
tures (Table II). Analysis (Chou and Fasman, 1984) 
73 
‘W LYS I Lei Phe Ala 
HPRT Flint 
TAT AAA TTm TTT GCT 
222 
TAT AAA TTO TTT GCT 
Normal TYr LYS I Phe Phe Ala 
Fig. 2. Mutant nucleotide (nt 214-228) and aa (7 l-75) sequence 
of HPRTFlint compared to normal. The C -+ A transversion at nt 
222 (box) causes a Phe + Leu substitution at aa 73 (box). 
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TABLE II 
Conservation of Phe-73 among various phosphoribosyltransferasesa 
Phospho~bosyl- 
transferases 
Amino acid residues from position 69 to 76b 
69 70 71 12 
Reference c 







E. coli APRT 
E. coli XGPRT 
































































a Sequences are aligned to give maximal overlap of predicted secondary structure (Chou and Fasman, 1978) 
b Residue numbers correspond to the amino acid sequence of the mature human enzyme isolated from erythrocytes (Wilson et al., 1983) 
c A, Wilson et al. (1982b); B,C, Konecki et al. (1983); D, Wilson et al. (1986); E, Dush et al. (1985); F, Hershey and Taylor (1986); G, 
Pratt and Subramani (1983). H, Poulsen et al. (1983). 
of the region spanning aa residues 69 to 76 predicts 
an a-helical region directly adjacent to a fi-turn. Leu, 
which has a stronger propensity toward a-helical 
formation than does Phe, could result in the ex- 
tension of a helix into what normally exists as a turn. 
Furthermore, it is likely that the replacement of the 
strongly conserved aromatic side chain at this po- 












72 bp 264 bp 
Fig. 3. Map of plasmid pSPH1 used in RNase A mapping analysis. The pSP64 plaamid was cleaved with Hind111 + Sal1 and ligated 
to the 336-bp HindIII-XhoI fragment of normal HPRT cDNA sequence. The resultant recombinant plasmid, pSPH1, was linearized 
with EcoRI (E). Transcription with SP6 RNA poiymerase using the SP6 promoter results in the production of the antisense strand of 
HPRT sequence. The probe, hybridized to normal RNA or to RNA of patient A.C., is cleaved with RNase A and RNase Tt, giving 
either a 336-bp fragment (completely protected) or 72- and 264-bp fragments, respectively. The actual cleavage products are shown in 
Fig. 4. HP, HPRT sequences; SP6, SP6 promoter; vertical dashes and single line, vector sequences; blackened bar, RNA probe; stippled 
bar, mRNA sequences. 
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the preceding turn. There are numerous examples of 
the impact of single amino acid substitutions on the 
rate of folding and/or assembly of proteins in vivo 
Fig. 4. RNase A mapping of HPRT,,;,,. RNase cleavage pro- 
ducts of approx. 72 bp and 264 bp (see Fig. 3) are seen in RNA 
from patient A.C., compared to the completely protected frag- 
ments in the adjacent lane (normal). RNase A and RNase Tl 
digestion (Gibbs and Caskey, 1986) were followed by two ethanol 
precipitations. The RNase-digested RNA was then electro- 
phoresed in a 6% denaturing polyacrylamide gel containing 8 M 
urea. The gel was dried and autoradiographed for 12 to 16 h. 
(Beasty et al., 1986). Thus, the impact of this muta- 
tion may also be at the levels of both secondary and 
tertiary structures. 
(c) RNase A mapping 
RNase A mapping of A.C. mRNA was done using 
pSPH1 which is the pSP64 plasmid (Promega 
Biotech) into which the XhoI-Hind111 fragment 
representing bp 149 to 485 of normal human HPRT 
cDNA has been cloned (Fig. 3). RNA transcripts 
were made using [ a-32P]GTP and hybridized to 100 
pg of total RNA, as described by Gibbs and Caskey 
(1987). 
A mismatch between the cDNA clones of 
HPRTFIi,, and normal HPRT mRNA was con- 
firmed using this approach (Figs. 3 and 4). The 
336-bp fragment spanning the area of the mutation 
was cleaved when hybridized to RNA isolated from 
lymphoblasts derived from patient A.C., yielding the 
cleavage products of 72 and 264 bp, appropriate 
sizes for a mutation site at bp 222 (Fig. 4). RNase 
cleavage was incomplete as noted by the presence of 
the 336-bp fragment. No cleavage products were 
seen when a labeled RNA probe spanning bp 658 
was used (not shown), providing further evidence 
that the transition at 658 in pHPAC8 is a cloning 
artifact. 
(d) Conclusions 
Cloning of mutant forms of HPRT cDNA from 
deficient subjects is a rapid method for determining 
those structural alterations which render the enzyme 
inactive and/or unstable. This is the first report of a 
mutation in this region of the HPRT molecule being 
responsible for a complete absence of enzyme 
protein. The high degree of evolutionary con- 
servation of amino acid sequence in this region, as 
well as the profound impact of this mutation within 
that region, suggest an important role for this se- 
quence in the maintenance of normal protein stability 
and activity. 
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